5. (Twice Amended) A composition for the treatment of glaucoma and ocular hypertension comprising a therapeutically active and physiologically acceptable amount of a prostaglandin analogue which is a selective agonist for EP_1 prostanoid receptors, or a pharmaceutically acceptable salt or ester thereof, wherein the prostaglandin analogue is 13,14-dihydro-17-(3-fluorophenyl)-18,19,20-trinor-PGE_2 or an alkyl ester thereof.

18. (Amended) The method according to claim 8, wherein R is C_{1-10} alkyl, C_{3-8} cycloalkyl or aryl-C_{2-5} alkyl.

19. (Amended) The method according to claim 8, wherein R1 is C_{3-7} cycloalkyl or C_{3-7} cycloalkenyl.

20. (Amended) The method according to claim 8, wherein R2 is hydrogen, hydroxy, methyl, ethyl, methoxy or OCOR4, wherein R4 is C_{1-10} alkyl or C_{3-8} cycloalkyl.

21. (Amended) The method according to claim 8, wherein R3 is a straight or branched chain saturated or unsaturated alkyl group having 3-8 carbon atoms, optionally interrupted by one or more heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen, each carbon atom optionally substituted with a substituent selected from C_{1-5} alky, hydroxy and carbonyl groups, wherein the hydroxy and carbonyl are attached to carbon 15 of the prostaglandin structure, and said alkyl group optionally containing a C_{3-8} cycloalkyl, optionally mono- or independently tri-substituted with C_{1-3} alkyl, C_{1-3} alkoxy, hydroxy, nitro, trifluoromethyl or halogen.